Posted in:Legal Litigation Spotlight: The Infliximab (Remicade®) Litigation By Daniel McCallum April 19, 2017 Comments are off Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and... Read more Tagged with: BPCIA, Celltrion, District Court, Featured, Federal Court, Hospira, Inflectra®, Infliximab, Janssen, Janssen v. Celltrion, Legal, Litigation, Litigation Spotlight, Notice Requirement, Patent Dance, Pfizer, Remicade® http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus